
The government has capped trade margins at 30% of the maximum retail price (MRP) for all non-scheduled anti-cancer drugs, a move it says could reduce medicine prices by up to 70% and save patients around Rs 2,500 crore annually. The measure, announced on Thursday, 8 October, covers branded, generic, domestic and imported drugs, including patented and non-patented medicines.
The National Pharmaceutical Pricing Authority (NPPA) found average trade mark-ups of about 170%, reaching 700% in some cases. An expert committee under the Directorate General of Health Services will finalise the list of medicines, which officials say includes 110 drugs, 35 of them patented. Manufacturers must maintain current production levels to ensure availability.
The decision builds on a 2019 intervention covering 42 drugs that reduced MRPs by up to 91% and saved Rs 984 crore across 526 brands. The Supreme Court is scheduled to hear the matter on 12 October, and the committee's report is due by 14 October.
Update, 11 October 2026: On 10 October, Karnataka urged the Centre to extend the price caps to cardiac and kidney drugs, The Hindu and Hindustan Times report. Health Minister UT Khader said the NPPA directed the health ministry to submit the list of cancer medicines by 14 October. Hospital stocks rallied up to 5% on 9 October, with Jefferies and ICICI Securities estimating limited EBITDA impact, CNBCTV18 and Business Standard report. HealthCare Global's chairman warned the cap could keep new drugs out of India.
The coverage is almost uniformly neutral reporting, with most outlets relaying the government's official figures and estimated savings. The Indian Express and The Hindu add context on the 2019 pilot and the role of the Supreme Court, while Business Today and CNBCTV18 include industry reactions that welcome the move but flag implementation risks. The Times of India and The Print carry critical voices from the Working Group on Access to Medicines, arguing that a margin cap alone will not make patented drugs like Ribociclib or Pembrolizumab affordable. Fortune India and Business Line echo this concern. The government's framing emphasises patient savings and curbing profiteering, while critics point to rising prices even after the 2019 cap. The Supreme Court hearing on 12 October will test whether the government's action satisfies the court's demand for broader price controls.
Coverage: 62 sources, 62 neutral
Sources (62): economictimes.indiatimes.com (neutral report), timesofindia.indiatimes.com (neutral report), news9live.com (neutral report), cnbctv18.com (neutral report), mathrubhumi.com (neutral report), businesstoday.in (neutral report), sentinelassam.com (neutral report), thehindubusinessline.com (neutral report), timesofindia.indiatimes.com (2) (neutral report), indianexpress.com (neutral report), yespunjab.com (neutral report), business-standard.com (neutral report), rediff.com (neutral report), morungexpress.com (neutral report), indiatvnews.com (neutral report), economictimes.indiatimes.com (2) (neutral report), livemint.com (neutral report), thehindu.com (neutral report), thehansindia.com (neutral report), medicaldialogues.in (neutral report), timesofindia.indiatimes.com (3) (neutral report), hindustantimes.com (neutral report), thefederal.com (neutral report), cnbctv18.com (2) (neutral report), thehansindia.com (2) (neutral report), mathrubhumi.com (2) (neutral report), openthemagazine.com (neutral report), cnbctv18.com (3) (neutral report), cnbctv18.com (4) (neutral report), economictimes.indiatimes.com (3) (neutral report), business-standard.com (2) (neutral report), economictimes.indiatimes.com (4) (neutral report), timesnownews.com (neutral report), fortuneindia.com (neutral report), livemint.com (2) (neutral report), cnbctv18.com (5) (neutral report), thesouthfirst.com (neutral report), cnbctv18.com (6) (neutral report), timesnownews.com (2) (neutral report), assamtribune.com (neutral report), cnbctv18.com (7) (neutral report), cnbctv18.com (8) (neutral report), abplive.com (neutral report), eastmojo.com (neutral report), theprint.in (neutral report), telanganatoday.com (neutral report), medicaldialogues.in (2) (neutral report), thehindubusinessline.com (2) (neutral report), timesofindia.indiatimes.com (4) (neutral report), thefederal.com (2) (neutral report), thehindu.com (2) (neutral report), hindustantimes.com (2) (neutral report), deccanchronicle.com (neutral report), indianexpress.com (2) (neutral report), deccanherald.com (neutral report), deccanherald.com (2) (neutral report), hindustantimes.com (3) (neutral report), theprint.in (2) (neutral report), tripuratimes.com (neutral report), siasat.com (neutral report), thehansindia.com (3) (neutral report), businesstoday.in (2) (neutral report)
This brief was synthesised by AI from the 62 sources linked above, so one read covers every framing they carry. Methodology and corrections.